Cantor Fitzgerald Reiterates Overweight on Keros Therapeutics
Perspective Therapeutics Analyst Ratings
4 Stocks to Watch on Friday: INTU, MSTR and More
Stifel Upgrades Pebblebrook Hotel Trust, Downgrades DiamondRock Hospitality
Loop Capital Maintains Buy on Atkore, Lowers Price Target to $115
A Look at Leslies's Upcoming Earnings Report
Fluence Energy's Earnings Outlook
Expert Outlook: MaxLinear Through The Eyes Of 4 Analysts
Amphastar Pharma Analyst Ratings
This Nike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Wells Fargo Initiates Coverage On MaxLinear With Equal-Weight Rating, Announces Price Target of $14
MaxLinear Analyst Ratings
EVgo Powers On Despite Trump Shake-Up: Analyst Projects 16% US Battery EV Penetration By 2030
Spain Consumer Regulator Fines Ryanair for Charging Extra Fees for Hand Luggage, Seating
This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Halozyme Therapeutics Shares Are Trading Higher After the Company Announced It Withdrew Plans to Acquire Evotec.
Replimune Climbs After Updates on Lead Drug
Intuit Issues Weak Forecast, Joins Reddit And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Community Health Sys Analyst Ratings
Atkore Analyst Ratings